Verona Pharma Plc Return on Equity

Verona Pharma Plc (VRNA) currently reports a ROE of -29.18%. That is below the Healthcare sector average of 29.39%. Use the charts on this page to explore Verona Pharma Plc's ROE history and peer comparisons.

Verona Pharma Plc's ROE of -29.18% is lower than the Healthcare sector average of 29.39%. That is roughly 199.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Verona Pharma Plc's current -29.18% should be judged against Healthcare norms (sector average: 29.39%) and against VRNA's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -29.18%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 29.39%. From there, open related valuation or income-statement pages for Verona Pharma Plc, and consider following VRNA for alerts when major investors trade the stock.

Verona Pharma Plc is classified in the Healthcare sector. On ROE, it currently shows -29.18% versus a sector average near 29.39%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing VRNA with unrelated industries.